Open Access

Ataxia‑telangiectasia with a novel ATM gene mutation and Burkitt leukemia: A case report

  • Authors:
    • Fanghua Ye
    • Wenwen Chai
    • Minghua Yang
    • Min Xie
    • Liangchun Yang
  • View Affiliations

  • Published online on: September 17, 2018     https://doi.org/10.3892/mco.2018.1721
  • Pages: 493-498
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Ataxia‑telangiectasia (A‑T) is an infrequent autosomal recessive disorder that involves multiple systems and is characterized by progressive cerebellar ataxia, oculocutaneous telangiectasias, radiosensitivity, immune deficiency with recurrent respiratory infections, and a tendency to develop lymphoid malignancies. A‑T is caused by mutations in the ATM gene, with >1,000 mutations reported to date and gradually increasing in number. Patients with A‑T have an increased incidence of cancers. The aim of the present study was to retrospectively review the case of a patient who presented at the age of 5 years with cerebellar ataxia without telangiectasia, and was diagnosed with Burkitt leukemia by bone marrow biopsy and molecular testing at the age of 7 years at the Xiangya Hospital of Central South University (Changsha, China). The patient received chemotherapy with the pediatric CCCG‑BNHL‑2015 regimen (R4 group) and achieved a complete remission after 2 courses. However, recurrent respiratory infections and thrombosis occurred during chemotherapy. The diagnosis of A‑T was confirmed by uncovering two variants of the ATM gene, including c.742C>T (p.R248X; rs730881336) in exon 7 and c.6067‑c.6068 ins GAGGGAAGAT in exon 41 by whole‑exome sequencing. Unfortunately, the patient's parents refused follow‑up treatment and he succumbed to recurrent severe infections 4 months after the diagnosis of Burkitt leukemia. The diagnosis of A‑T may be challenging, as its phenotype can be incomplete early in the course of the disease. Detailed medical history, characteristic clinical manifestations and increasingly developed exome sequencing techniques may be helpful in diagnosing this rare disease. Management should be based on multidisciplinary guidance and other treatment options must be investigated in the future.
View Figures
View References

Related Articles

Journal Cover

November 2018
Volume 9 Issue 5

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Ye, F., Chai, W., Yang, M., Xie, M., & Yang, L. (2018). Ataxia‑telangiectasia with a novel ATM gene mutation and Burkitt leukemia: A case report. Molecular and Clinical Oncology, 9, 493-498. https://doi.org/10.3892/mco.2018.1721
MLA
Ye, F., Chai, W., Yang, M., Xie, M., Yang, L."Ataxia‑telangiectasia with a novel ATM gene mutation and Burkitt leukemia: A case report". Molecular and Clinical Oncology 9.5 (2018): 493-498.
Chicago
Ye, F., Chai, W., Yang, M., Xie, M., Yang, L."Ataxia‑telangiectasia with a novel ATM gene mutation and Burkitt leukemia: A case report". Molecular and Clinical Oncology 9, no. 5 (2018): 493-498. https://doi.org/10.3892/mco.2018.1721